Safety Study of PLX108-01 in Patients With Solid Tumors
Status:
Completed
Trial end date:
2018-10-25
Target enrollment:
Participant gender:
Summary
PLX3397 is a selective inhibitor of Fms, Kit, and oncogenic Flt3 activity. The primary
objective of this study is to evaluate the safety and pharmacokinetics of orally administered
PLX3397 in patients with advanced, incurable, solid tumors in which these target kinases are
linked to disease pathophysiology. The secondary objective is to measure the pharmacodynamic
activity of PLX3397 via blood, plasma and urine biomarkers of Fms activity.